Ensysce Biosciences (ENSC) EBIT Margin (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly EBIT Margin of 758.68% for Q3 2025, down 77754.0% year-over-year from N/an in Q3 2024, and down 494.39% quarter-over-quarter from 127.64% in Q2 2025.
Ensysce Biosciences (ENSC) EBIT Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported EBIT Margin for 6 consecutive years, with 758.68% the latest figure, recorded in Q3 2025.
- In Q3 2025, EBIT Margin fell 77754.0% year-over-year to 758.68%; the TTM figure through Sep 2025 stood at 245.89% (down 10319.0% YoY), while the FY2024 annual figure was 129.18%, up 35135.0% from the prior year.
- EBIT Margin slipped to 758.68% in Q3 2025 per ENSC's latest filing, from 127.64% in the prior quarter.
- Across five years, EBIT Margin topped out at 18.86% in Q3 2024 and bottomed at 3400.56% in Q2 2022.
- Historically, EBIT Margin has averaged 719.09% across 5 years, with a median of 467.7% in 2023.
- Annual changes were most pronounced in 2022 — EBIT Margin tumbled 330774 bps — and 2023, when it surged 293286 bps.
- Ensysce Biosciences' EBIT Margin stood at 122.71% in 2021, then sank by 253 bps to 432.57% in 2022, then plunged by 42 bps to 612.72% in 2023, then soared by 55 bps to 274.34% in 2024, then slumped by 177 bps to 758.68% in 2025.
- Business Quant data shows ENSC's EBIT Margin at 758.68% in Q3 2025, 127.64% in Q2 2025, and 149.08% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Ensysce Biosciences | 935,232.79 | -3.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -758.68% |
| Jun 30, 2025 | -127.64% |
| Mar 31, 2025 | -149.08% |
| Dec 31, 2024 | -274.34% |
| Sep 30, 2024 | 18.86% |
| Jun 30, 2024 | -1,075.62% |
| Mar 31, 2024 | -602.82% |
| Dec 31, 2023 | -612.72% |
| Sep 30, 2023 | -621.83% |
| Jun 30, 2023 | -467.70% |
| Mar 31, 2023 | -324.36% |
| Dec 31, 2022 | -432.57% |
| Sep 30, 2022 | -2,206.30% |
| Jun 30, 2022 | -3,400.56% |
| Mar 31, 2022 | -796.36% |
| Dec 31, 2021 | -122.71% |
| Sep 30, 2021 | -1,406.28% |
| Jun 30, 2021 | -92.82% |
| Mar 31, 2021 | -209.23% |
| Dec 31, 2020 | -262.51% |